Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF injection for temporomandibular joint osteoarthritis
NL-OMON44586Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of autologous adipose stromal vascular fraction in Temporomandibular Osteoarthritis and temporomandibular disorder (TMD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: VAS pain during movement and VAS pain at rest. Planned start Aug 2017; status: withdrawn.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
Temporomandibular Osteoarthritistemporomandibular disorder (TMD)
Beyond the preview
Go deeper on NL-OMON44586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44586.